1. Home
  2. MBOT vs STTK Comparison

MBOT vs STTK Comparison

Compare MBOT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microbot Medical Inc.

MBOT

Microbot Medical Inc.

HOLD

Current Price

$2.09

Market Cap

134.3M

Sector

Health Care

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.69

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBOT
STTK
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MBOT
STTK
Price
$2.09
$3.69
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$8.75
$4.00
AVG Volume (30 Days)
2.0M
467.7K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3,119.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.08
$0.69
52 Week High
$4.67
$3.70

Technical Indicators

Market Signals
Indicator
MBOT
STTK
Relative Strength Index (RSI) 44.46 79.08
Support Level $1.95 $3.15
Resistance Level $2.14 $3.29
Average True Range (ATR) 0.12 0.22
MACD -0.02 0.03
Stochastic Oscillator 22.50 89.69

Price Performance

Historical Comparison
MBOT
STTK

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: